[{"id":"0b6e5ad5-c4b9-4e11-ac82-4f01f7ab9b5f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04834778","created_at":"2021-04-08T13:52:24.698Z","updated_at":"2024-07-02T16:35:15.757Z","phase":"Phase 1","brief_title":"A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)","source_id_and_acronym":"NCT04834778","lead_sponsor":"HiberCell, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HC-5404"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 06/08/2021","start_date":" 06/08/2021","primary_txt":" Primary completion: 12/07/2023","primary_completion_date":" 12/07/2023","study_txt":" Completion: 01/30/2024","study_completion_date":" 01/30/2024","last_update_posted":"2024-03-08"}]